Even though a number of liposomal chemotherapeutic drug formulations have been licenced for cancer treatment, increased Drug Delivery through these liposomes is primarily achieved through passive methods, such as improved permeability and retention. Antibodies Immunoliposomes with the aim of cell-specific targeted medication delivery are in different stages of development. The high molecular weight and negatively charged of siRNA duplexes provide significant obstacles to intracellular distribution and efficient cellular uptake, which are essential for the widespread application of RNAi in vivo. The integration of EphA2 siRNA into neutral liposomes, which, in animal studies, provides a highly effective method of lowering tumour EphA2 expression and anticancer action, either alone or with increased activity when paired with paclitaxel, is one example of how this is being addressed. Future design of nanoparticles that preferentially aggregate at the tumour site and, if loaded with medicine, convey their cargo directly to the tumour, may be made possible by the aberrant nature of the tumor's vasculature. The utilisation of pH-sensitive liposomes, cell-penetrating proteins and peptides, and immunoliposomes targeting intracellular antigens is also being developed for Intracellular Targeted Medication Delivery. Delivery methods to intracellular targets, such as the nucleus for gene therapy agents and the mitochondrion for pro-apoptotic medications and pharmaceuticals that target the mitochondrial genome, are also being developed.
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Exploring classical ayurvedic drugs in hypertension
Prashant Bhokardankar, Datta Meghe Ayurved College, India
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : A unique role and and impact of catalytic antibodies (abzymes) in clinical practice: A novel strategy for predicting and preventing relapse in chronic autoimmune conditions
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promise of nanotechnology in personalized & precision medicine: Drug discovery & development being partnered with nanotechnologies via the revolution at the nanoscale
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : The promising future of the unique translational tool to manage beta-cell population renewal and regeneration to secure the post-diabetic period
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Easily injectable, organic solvent free self assembled hydrogel platform for endoscope mediated gastrointestinal polypectomy
Hitasha Vithalani , IIT Gandhinagar, India